Universidade De Santiago De Compostela

Universidade De Vigo

Universidad De Vigo

Fundacion Biomedica Galicia Sur

Pedro Besada Pereira

Tamara Costas Caamaño

Ma Del Carmen Costas Lago

Carmen Teran Moldes

Saida Ortolano

Noemí Vila Molares

Ma Del Carmen Terán Moldes

Dolores Viña Castelao

Mª Del Carmen TERÁN Moldes

Mª Del Carmen Costas Lago

Dolores VIÑA Castelao

The present invention relates to the use of galactose analogues of formula (I) with the capacity to stabilize the structure of the #-GalA enzyme, for the treatment of lysosomal storage diseases and, in a preferred embodiment, for the treatment of Fabry disease. In addition, the present invention relates to pharmacological compositions having an effective amount of at least one of the galactose analogues described in the present document for the treatment of lysosomal storage diseases and, in a preferred embodiment, for the treatment of Fabry disease.

Use of pharmacological chaperones for the treatment of lysosomal storage diseases

The present invention refers to pyridazin-3(2H)-one derivatives of general structure I, II and III, which are selective MAO-B inhibitors, and to the use thereof for preparing medicaments intended to treat disorders derived from MAO-B hyperactivity, particularly degenerative disorders of the central nervous system (CNS), such as Parkinson's disease (PD), Alzheimer's disease (AD) and other dementias. These are pyridazin-3(2H)-one derivatives having dithiocarbamate moieties bonded to position 4, 5 or 6 through an alkyl chain of variable length (n=1, 2, 3). This invention is also directed to the preparation of said compounds. 

Pyridazin-3(2H)-one derivatives as monoamine oxidase selective isoform B inhibitors

Growing community of inventors

Vigo, Spain

Pedro Besada Pereira